TB-500 and Thymosin Beta-4: Why the Difference Matters
VA Health & Wellness2 min read
In short
TB-500 is a name used for a peptide fragment associated with thymosin beta-4. Research about the full-length molecule cannot automatically establish the effects of that fragment. FDA’s 2026 TB-500 assessment identified insufficient clinical evidence for the evaluated wound-healing use and important questions about product identity and safety.
On this page
Key takeaways
- Why is the name confusing?
Related names often appear together in peptide discussions.
- Can full-length peptide research support a fragment?
It can supply context for a research hypothesis, but it cannot make the products interchangeable.
- What does the clinical evidence establish?
FDA's 2026 assessment did not identify clinical information sufficient to evaluate TB-500 products for the nominated wound-healing use.
- What is its FDA and compounding status?
No approved TB-500 product was identified in the reviewed assessment.
- What questions belong in a recovery appointment?
Describe the injury or wound and ask what assessment is needed.
- Learn before selecting a product
Our BPC-157/TB-500 blend article addresses additional combination questions.
Why is the name confusing?
Related names often appear together in peptide discussions. FDA's TB-500 briefing evaluates the seven-amino-acid fragment and its free-base and acetate forms. [S11] (opens in a new tab) That is a specific substance, not a blanket category covering every thymosin beta-4 product. Before accepting a research claim, ask the provider or pharmacist to identify the active ingredient precisely. A commercial nickname is not enough to determine whether two preparations match.
Can full-length peptide research support a fragment?
It can supply context for a research hypothesis, but it cannot make the products interchangeable. Different molecules need their own evidence. Read the paper's methods to see what was actually administered, by which route, and for what condition. If an advertisement uses another molecule's research, ask for the explanation of why those findings apply. Without that connection, the comparison is a suggestion rather than a demonstrated treatment effect.
What does the clinical evidence establish?
FDA's 2026 assessment did not identify clinical information sufficient to evaluate TB-500 products for the nominated wound-healing use. [S11] (opens in a new tab) This does not support claims that TB-500 predictably repairs tissue, resolves chronic inflammation, or accelerates return to exercise. “No adequate evidence of benefit” is also different from proof that a substance has no biological effects. The important clinical point is that reliable patient outcomes have not been established.
What is its FDA and compounding status?
No approved TB-500 product was identified in the reviewed assessment. The codified 503A bulks list retrieved for this project does not list TB-500. [S08] (opens in a new tab) A committee review or favorable commentary should not be described as FDA drug approval. The exact preparation and current policies require separate review before any prescribing or dispensing decision. Avoid drawing a legal conclusion from a seller's claim of availability.
What questions belong in a recovery appointment?
Describe the injury or wound and ask what assessment is needed. Discuss evidence-supported options for that specific problem, the expected course, and when a change in symptoms needs evaluation. If TB-500 is proposed, ask for evidence on the actual substance rather than on a related peptide. Also ask how the provider would explain benefits, uncertainties, and alternatives in the informed-consent discussion.
Learn before selecting a product
Our BPC-157/TB-500 blend article addresses additional combination questions. VA Health & Wellness's care-process page can help you prepare for a visit. This article provides general education and does not recommend TB-500 as a substitute for wound care, rehabilitation, or a diagnosis.
Frequently asked questions
Sources
[S08] eCFR, Office of the Federal Register: 21 CFR 216.23 (opens in a new tab)
